Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure
Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy - HF (ATHENA-HF)
Status: Enrolling
Updated:  11/29/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure
Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy - HF (ATHENA-HF)
Status: Enrolling
Updated: 11/29/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure
Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy - HF (ATHENA-HF)
Status: Enrolling
Updated:  11/29/2016
Jefferson Medical College
mi
from
Philadelphia, PA
Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure
Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy - HF (ATHENA-HF)
Status: Enrolling
Updated: 11/29/2016
Jefferson Medical College
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure
Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy - HF (ATHENA-HF)
Status: Enrolling
Updated:  11/29/2016
Michael Debakey VA Medical Center
mi
from
Houston, TX
Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure
Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy - HF (ATHENA-HF)
Status: Enrolling
Updated: 11/29/2016
Michael Debakey VA Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure
Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy - HF (ATHENA-HF)
Status: Enrolling
Updated:  11/29/2016
University of Utah School of Medicine
mi
from
Salt Lake City, UT
Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure
Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy - HF (ATHENA-HF)
Status: Enrolling
Updated: 11/29/2016
University of Utah School of Medicine
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure
Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy - HF (ATHENA-HF)
Status: Enrolling
Updated:  11/29/2016
Utah VA Medical Center
mi
from
Salt Lake City, UT
Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure
Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy - HF (ATHENA-HF)
Status: Enrolling
Updated: 11/29/2016
Utah VA Medical Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure
Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy - HF (ATHENA-HF)
Status: Enrolling
Updated:  11/29/2016
University of Vermont/Fletcher Allen Health Care
mi
from
Burlington, VT
Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure
Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy - HF (ATHENA-HF)
Status: Enrolling
Updated: 11/29/2016
University of Vermont/Fletcher Allen Health Care
mi
from
Burlington, VT
Click here to add this to my saved trials
Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects
An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and Subjects With Moderate Hepatic Impairment
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Miami, FL
Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects
An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and Subjects With Moderate Hepatic Impairment
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects
An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and Subjects With Moderate Hepatic Impairment
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Orlando, FL
Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects
An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and Subjects With Moderate Hepatic Impairment
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
A Multicenter, Randomized, 12 Week, Double-blind, Placebo-controlled, Parallel-group, Phase IIa Study Using 18F Fluorodeoxyglucose (FDG)-PET to Measure the Effects of Rilapladib on Macrophage Activity in Subjects With Atherosclerosis
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Boston, MA
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
A Multicenter, Randomized, 12 Week, Double-blind, Placebo-controlled, Parallel-group, Phase IIa Study Using 18F Fluorodeoxyglucose (FDG)-PET to Measure the Effects of Rilapladib on Macrophage Activity in Subjects With Atherosclerosis
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
A Multicenter, Randomized, 12 Week, Double-blind, Placebo-controlled, Parallel-group, Phase IIa Study Using 18F Fluorodeoxyglucose (FDG)-PET to Measure the Effects of Rilapladib on Macrophage Activity in Subjects With Atherosclerosis
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Brockton, MA
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
A Multicenter, Randomized, 12 Week, Double-blind, Placebo-controlled, Parallel-group, Phase IIa Study Using 18F Fluorodeoxyglucose (FDG)-PET to Measure the Effects of Rilapladib on Macrophage Activity in Subjects With Atherosclerosis
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Brockton, MA
Click here to add this to my saved trials
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
A Multicenter, Randomized, 12 Week, Double-blind, Placebo-controlled, Parallel-group, Phase IIa Study Using 18F Fluorodeoxyglucose (FDG)-PET to Measure the Effects of Rilapladib on Macrophage Activity in Subjects With Atherosclerosis
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Haverhill, MA
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
A Multicenter, Randomized, 12 Week, Double-blind, Placebo-controlled, Parallel-group, Phase IIa Study Using 18F Fluorodeoxyglucose (FDG)-PET to Measure the Effects of Rilapladib on Macrophage Activity in Subjects With Atherosclerosis
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Haverhill, MA
Click here to add this to my saved trials
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
A Multicenter, Randomized, 12 Week, Double-blind, Placebo-controlled, Parallel-group, Phase IIa Study Using 18F Fluorodeoxyglucose (FDG)-PET to Measure the Effects of Rilapladib on Macrophage Activity in Subjects With Atherosclerosis
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Linden, NJ
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
A Multicenter, Randomized, 12 Week, Double-blind, Placebo-controlled, Parallel-group, Phase IIa Study Using 18F Fluorodeoxyglucose (FDG)-PET to Measure the Effects of Rilapladib on Macrophage Activity in Subjects With Atherosclerosis
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Linden, NJ
Click here to add this to my saved trials
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
A Multicenter, Randomized, 12 Week, Double-blind, Placebo-controlled, Parallel-group, Phase IIa Study Using 18F Fluorodeoxyglucose (FDG)-PET to Measure the Effects of Rilapladib on Macrophage Activity in Subjects With Atherosclerosis
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
New York, NY
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
A Multicenter, Randomized, 12 Week, Double-blind, Placebo-controlled, Parallel-group, Phase IIa Study Using 18F Fluorodeoxyglucose (FDG)-PET to Measure the Effects of Rilapladib on Macrophage Activity in Subjects With Atherosclerosis
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
A Multicenter, Randomized, 12 Week, Double-blind, Placebo-controlled, Parallel-group, Phase IIa Study Using 18F Fluorodeoxyglucose (FDG)-PET to Measure the Effects of Rilapladib on Macrophage Activity in Subjects With Atherosclerosis
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
North Massapequa, NY
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
A Multicenter, Randomized, 12 Week, Double-blind, Placebo-controlled, Parallel-group, Phase IIa Study Using 18F Fluorodeoxyglucose (FDG)-PET to Measure the Effects of Rilapladib on Macrophage Activity in Subjects With Atherosclerosis
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
North Massapequa, NY
Click here to add this to my saved trials
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
A Multicenter, Randomized, 12 Week, Double-blind, Placebo-controlled, Parallel-group, Phase IIa Study Using 18F Fluorodeoxyglucose (FDG)-PET to Measure the Effects of Rilapladib on Macrophage Activity in Subjects With Atherosclerosis
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Warwick, RI
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
A Multicenter, Randomized, 12 Week, Double-blind, Placebo-controlled, Parallel-group, Phase IIa Study Using 18F Fluorodeoxyglucose (FDG)-PET to Measure the Effects of Rilapladib on Macrophage Activity in Subjects With Atherosclerosis
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Warwick, RI
Click here to add this to my saved trials
Environmental or Nasal Cannula Oxygen for Preterm Infants Receiving Oxygen Therapy: a Randomized Cross-over Pilot Study
Environmental or Nasal Cannula Oxygen for Preterm Infants Receiving Oxygen Therapy: a Randomized Cross-over Pilot Study
Status: Enrolling
Updated:  11/30/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Environmental or Nasal Cannula Oxygen for Preterm Infants Receiving Oxygen Therapy: a Randomized Cross-over Pilot Study
Environmental or Nasal Cannula Oxygen for Preterm Infants Receiving Oxygen Therapy: a Randomized Cross-over Pilot Study
Status: Enrolling
Updated: 11/30/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement: the ACIST-FFR Study
Status: Enrolling
Updated:  12/5/2016
Scripps Green Hospital
mi
from
La Jolla, CA
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement: the ACIST-FFR Study
Status: Enrolling
Updated: 12/5/2016
Scripps Green Hospital
mi
from
La Jolla, CA
Click here to add this to my saved trials
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement: the ACIST-FFR Study
Status: Enrolling
Updated:  12/5/2016
Long Beach VA Medical Center
mi
from
Long Beach, CA
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement: the ACIST-FFR Study
Status: Enrolling
Updated: 12/5/2016
Long Beach VA Medical Center
mi
from
Long Beach, CA
Click here to add this to my saved trials
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement: the ACIST-FFR Study
Status: Enrolling
Updated:  12/5/2016
Stanford School of Medicine
mi
from
Stanford, CA
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement: the ACIST-FFR Study
Status: Enrolling
Updated: 12/5/2016
Stanford School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement: the ACIST-FFR Study
Status: Enrolling
Updated:  12/5/2016
University of Chicago Medicine
mi
from
Chicago, IL
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement: the ACIST-FFR Study
Status: Enrolling
Updated: 12/5/2016
University of Chicago Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement: the ACIST-FFR Study
Status: Enrolling
Updated:  12/5/2016
Iowa Heart Center, P.C.
mi
from
West Des Moines, IA
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement: the ACIST-FFR Study
Status: Enrolling
Updated: 12/5/2016
Iowa Heart Center, P.C.
mi
from
West Des Moines, IA
Click here to add this to my saved trials
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement: the ACIST-FFR Study
Status: Enrolling
Updated:  12/5/2016
Metropolitan Cardiology Heart and Vascular Institute
mi
from
Minneapolis, MN
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement: the ACIST-FFR Study
Status: Enrolling
Updated: 12/5/2016
Metropolitan Cardiology Heart and Vascular Institute
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement: the ACIST-FFR Study
Status: Enrolling
Updated:  12/5/2016
Univ of Minnesota
mi
from
Minneapolis, MN
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement: the ACIST-FFR Study
Status: Enrolling
Updated: 12/5/2016
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement: the ACIST-FFR Study
Status: Enrolling
Updated:  12/5/2016
Saint Louis University
mi
from
Saint Louis, MO
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement: the ACIST-FFR Study
Status: Enrolling
Updated: 12/5/2016
Saint Louis University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement: the ACIST-FFR Study
Status: Enrolling
Updated:  12/5/2016
Columbia University Medical Center and the New York Presbyterian Hospital
mi
from
New York, NY
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement: the ACIST-FFR Study
Status: Enrolling
Updated: 12/5/2016
Columbia University Medical Center and the New York Presbyterian Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement: the ACIST-FFR Study
Status: Enrolling
Updated:  12/5/2016
The Lindner Research Center, The Christ Hospital
mi
from
Cincinnati, OH
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement: the ACIST-FFR Study
Status: Enrolling
Updated: 12/5/2016
The Lindner Research Center, The Christ Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement: the ACIST-FFR Study
Status: Enrolling
Updated:  12/5/2016
Cleveland Cllinic Foundation
mi
from
Cleveland, OH
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement: the ACIST-FFR Study
Status: Enrolling
Updated: 12/5/2016
Cleveland Cllinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement: the ACIST-FFR Study
Status: Enrolling
Updated:  12/5/2016
Medstart Washington Hospital Center
mi
from
Washington,
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement: the ACIST-FFR Study
Status: Enrolling
Updated: 12/5/2016
Medstart Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
Exercise and Low-Dose Rapamycin in Older Adults With CAD:Cardiac Rehabilitation And Rapamycin in Elderly (CARE) Trial
Role of Exercise and Low-Dose Rapamycin on Age-Associated Impairments in Older Adults With Coronary Artery Disease: Cardiac Rehabilitation And Rapamycin in Elderly (CARE) Trial
Status: Enrolling
Updated:  12/6/2016
Mayo Clinic in Rochester and Mayo Health System sites in Austin and Albert Lea, Minnesota
mi
from
Rochester, MN
Exercise and Low-Dose Rapamycin in Older Adults With CAD:Cardiac Rehabilitation And Rapamycin in Elderly (CARE) Trial
Role of Exercise and Low-Dose Rapamycin on Age-Associated Impairments in Older Adults With Coronary Artery Disease: Cardiac Rehabilitation And Rapamycin in Elderly (CARE) Trial
Status: Enrolling
Updated: 12/6/2016
Mayo Clinic in Rochester and Mayo Health System sites in Austin and Albert Lea, Minnesota
mi
from
Rochester, MN
Click here to add this to my saved trials
NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions
NEWTON: A Single-center Open Label Study Evaluating Intravitreal Aflibercept Injection (IAI) for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions
Status: Enrolling
Updated:  12/7/2016
Northern California Retina Vitreous Associates
mi
from
Mountain View, CA
NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions
NEWTON: A Single-center Open Label Study Evaluating Intravitreal Aflibercept Injection (IAI) for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions
Status: Enrolling
Updated: 12/7/2016
Northern California Retina Vitreous Associates
mi
from
Mountain View, CA
Click here to add this to my saved trials
Effect of IV Acetaminophen on Patients in the Neurocritical Care Unit
Status: Enrolling
Updated:  12/8/2016
University of Utah
mi
from
Salt Lake City, UT
Effect of IV Acetaminophen on Patients in the Neurocritical Care Unit
Status: Enrolling
Updated: 12/8/2016
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
The Contribution of Endothelin to Vasomotor Function in Diseased Coronary Arteries
The Contribution of Endothelin to Vasoreactivity in Atherosclerotic Coronary Arteries
Status: Enrolling
Updated:  12/8/2016
Brigham and Women's Hosp
mi
from
Boston, MA
The Contribution of Endothelin to Vasomotor Function in Diseased Coronary Arteries
The Contribution of Endothelin to Vasoreactivity in Atherosclerotic Coronary Arteries
Status: Enrolling
Updated: 12/8/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
A Cohort Study to Test That There is a Low Risk of Recurrent VTE in Patients With a First Episode of Unprovoked VTE Who Stop Anticoagulant Therapy After 3 Months of Treatment in Response to Negative D-dimer Testing
Status: Enrolling
Updated:  12/12/2016
Lombardi Cancer Center
mi
from
Washington,
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
A Cohort Study to Test That There is a Low Risk of Recurrent VTE in Patients With a First Episode of Unprovoked VTE Who Stop Anticoagulant Therapy After 3 Months of Treatment in Response to Negative D-dimer Testing
Status: Enrolling
Updated: 12/12/2016
Lombardi Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
A Cohort Study to Test That There is a Low Risk of Recurrent VTE in Patients With a First Episode of Unprovoked VTE Who Stop Anticoagulant Therapy After 3 Months of Treatment in Response to Negative D-dimer Testing
Status: Enrolling
Updated:  12/12/2016
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
A Cohort Study to Test That There is a Low Risk of Recurrent VTE in Patients With a First Episode of Unprovoked VTE Who Stop Anticoagulant Therapy After 3 Months of Treatment in Response to Negative D-dimer Testing
Status: Enrolling
Updated: 12/12/2016
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
A Cohort Study to Test That There is a Low Risk of Recurrent VTE in Patients With a First Episode of Unprovoked VTE Who Stop Anticoagulant Therapy After 3 Months of Treatment in Response to Negative D-dimer Testing
Status: Enrolling
Updated:  12/12/2016
Brigham and Women's Hosp
mi
from
Boston, MA
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
A Cohort Study to Test That There is a Low Risk of Recurrent VTE in Patients With a First Episode of Unprovoked VTE Who Stop Anticoagulant Therapy After 3 Months of Treatment in Response to Negative D-dimer Testing
Status: Enrolling
Updated: 12/12/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
A Cohort Study to Test That There is a Low Risk of Recurrent VTE in Patients With a First Episode of Unprovoked VTE Who Stop Anticoagulant Therapy After 3 Months of Treatment in Response to Negative D-dimer Testing
Status: Enrolling
Updated:  12/12/2016
Beth Israel Deaconess Medical Centre
mi
from
Boston, MA
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
A Cohort Study to Test That There is a Low Risk of Recurrent VTE in Patients With a First Episode of Unprovoked VTE Who Stop Anticoagulant Therapy After 3 Months of Treatment in Response to Negative D-dimer Testing
Status: Enrolling
Updated: 12/12/2016
Beth Israel Deaconess Medical Centre
mi
from
Boston, MA
Click here to add this to my saved trials
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
A Cohort Study to Test That There is a Low Risk of Recurrent VTE in Patients With a First Episode of Unprovoked VTE Who Stop Anticoagulant Therapy After 3 Months of Treatment in Response to Negative D-dimer Testing
Status: Enrolling
Updated:  12/12/2016
Henry Ford Hospital
mi
from
Detroit, MI
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
A Cohort Study to Test That There is a Low Risk of Recurrent VTE in Patients With a First Episode of Unprovoked VTE Who Stop Anticoagulant Therapy After 3 Months of Treatment in Response to Negative D-dimer Testing
Status: Enrolling
Updated: 12/12/2016
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
A Cohort Study to Test That There is a Low Risk of Recurrent VTE in Patients With a First Episode of Unprovoked VTE Who Stop Anticoagulant Therapy After 3 Months of Treatment in Response to Negative D-dimer Testing
Status: Enrolling
Updated:  12/12/2016
UNC Thrombophilia Program
mi
from
Chapel Hill, NC
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
A Cohort Study to Test That There is a Low Risk of Recurrent VTE in Patients With a First Episode of Unprovoked VTE Who Stop Anticoagulant Therapy After 3 Months of Treatment in Response to Negative D-dimer Testing
Status: Enrolling
Updated: 12/12/2016
UNC Thrombophilia Program
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
A Cohort Study to Test That There is a Low Risk of Recurrent VTE in Patients With a First Episode of Unprovoked VTE Who Stop Anticoagulant Therapy After 3 Months of Treatment in Response to Negative D-dimer Testing
Status: Enrolling
Updated:  12/12/2016
Intermountain Medical Centre
mi
from
Murray, UT
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
A Cohort Study to Test That There is a Low Risk of Recurrent VTE in Patients With a First Episode of Unprovoked VTE Who Stop Anticoagulant Therapy After 3 Months of Treatment in Response to Negative D-dimer Testing
Status: Enrolling
Updated: 12/12/2016
Intermountain Medical Centre
mi
from
Murray, UT
Click here to add this to my saved trials
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
A Cohort Study to Test That There is a Low Risk of Recurrent VTE in Patients With a First Episode of Unprovoked VTE Who Stop Anticoagulant Therapy After 3 Months of Treatment in Response to Negative D-dimer Testing
Status: Enrolling
Updated:  12/12/2016
Hamilton General Hospital
mi
from
Hamilton,
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
A Cohort Study to Test That There is a Low Risk of Recurrent VTE in Patients With a First Episode of Unprovoked VTE Who Stop Anticoagulant Therapy After 3 Months of Treatment in Response to Negative D-dimer Testing
Status: Enrolling
Updated: 12/12/2016
Hamilton General Hospital
mi
from
Hamilton,
Click here to add this to my saved trials
Understanding "Heparin Resistance" in Cardiac Surgery
Understanding "Heparin Resistance" in Cardiac Surgery: Altered Heparin Responsiveness and Its Association With Acute Inflammatory Reactions
Status: Enrolling
Updated:  12/13/2016
Massachusetts General Hospital
mi
from
Boston, MA
Understanding "Heparin Resistance" in Cardiac Surgery
Understanding "Heparin Resistance" in Cardiac Surgery: Altered Heparin Responsiveness and Its Association With Acute Inflammatory Reactions
Status: Enrolling
Updated: 12/13/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.
A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction.
Status: Enrolling
Updated:  12/13/2016
Study Site 16101
mi
from
Birmingham, AL
A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.
A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction.
Status: Enrolling
Updated: 12/13/2016
Study Site 16101
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.
A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction.
Status: Enrolling
Updated:  12/13/2016
Study Site 16078
mi
from
Huntsville, AL
A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.
A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction.
Status: Enrolling
Updated: 12/13/2016
Study Site 16078
mi
from
Huntsville, AL
Click here to add this to my saved trials
A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.
A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction.
Status: Enrolling
Updated:  12/13/2016
Study Site - 16168
mi
from
Concord, CA
A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.
A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction.
Status: Enrolling
Updated: 12/13/2016
Study Site - 16168
mi
from
Concord, CA
Click here to add this to my saved trials
A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.
A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction.
Status: Enrolling
Updated:  12/13/2016
Study Site - 16168
mi
from
Concord, CA
A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.
A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction.
Status: Enrolling
Updated: 12/13/2016
Study Site - 16168
mi
from
Concord, CA
Click here to add this to my saved trials
A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.
A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction.
Status: Enrolling
Updated:  12/13/2016
Study Site 16147
mi
from
Sacramento, CA
A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.
A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction.
Status: Enrolling
Updated: 12/13/2016
Study Site 16147
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.
A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction.
Status: Enrolling
Updated:  12/13/2016
Study Site 16022
mi
from
Torrance, CA
A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.
A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction.
Status: Enrolling
Updated: 12/13/2016
Study Site 16022
mi
from
Torrance, CA
Click here to add this to my saved trials
A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.
A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction.
Status: Enrolling
Updated:  12/13/2016
Study Site 16130
mi
from
Littleton, CO
A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.
A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction.
Status: Enrolling
Updated: 12/13/2016
Study Site 16130
mi
from
Littleton, CO
Click here to add this to my saved trials
A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.
A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction.
Status: Enrolling
Updated:  12/13/2016
Study Site 16170
mi
from
Bridgeport, CT
A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.
A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction.
Status: Enrolling
Updated: 12/13/2016
Study Site 16170
mi
from
Bridgeport, CT
Click here to add this to my saved trials
A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.
A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction.
Status: Enrolling
Updated:  12/13/2016
Study Site 16135
mi
from
Danbury, CT
A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.
A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction.
Status: Enrolling
Updated: 12/13/2016
Study Site 16135
mi
from
Danbury, CT
Click here to add this to my saved trials